Gram-negative Bacterial Infections
Conditions
Brief summary
The purpose of this study is to characterize the intrapulmonary penetration of nacubactam in healthy volunteers. Nacubactam is a novel non-beta-lactam beta-lactamase inhibitor being developed as a combination therapy with the beta-lactam meropenem for the treatment of serious gram-negative bacterial infections. Adult male and female healthy participants will receive a single intravenous infusion of nacubactam co-administered with meropenem and then undergo a bronchoalveolar lavage (BAL) procedure to collect lung epithelial lining fluid (ELF) for measurement of intrapulmonary concentrations of nacubactam and meropenem.
Interventions
DRUGnacubactam
Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.
DRUGmeropenem
Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* 18 to 60 years of age, inclusive * Healthy, as judged by the Investigator and defined by the absence of evidence of any active or clinically significant chronic disease identified from a detailed medical and surgical history, physical examination including vital signs and 12-lead electrocardiogram (ECG), and laboratory safety test results * Body mass index (BMI) within the range 18-30 kilogram per square meter (kg/m\^2),inclusive * Non-smoker, or former smoker who has abstained from smoking for at least 6 months * Negative pregnancy test and agreement to comply with measures to prevent pregnancy in women * Refrain from sperm donation and agreement to comply with measures to prevent pregnancy in partner of childbearing potential for men
Exclusion criteria
* History of asthma or clinically significant lung disease * Any condition which contraindicates a BAL procedure * History of clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological, dermatological, immunological or allergic disease, metabolic disorder, cancer or cirrhosis * Clinically significant change in health status, as judged by the Investigator, or any major illness within the four weeks before screening, or clinically significant acute infection or febrile illness within the 14 days before screening * History of epilepsy (or known seizure disorder), brain lesions or other significant neurological disorders * Participation in any other clinical study involving an investigational medicinal product or device within 3 months before screening * Known history of clinically significant hypersensitivity or urticaria, or severe allergic reaction to any drug, in particular antibiotics * Donation or loss of over 500 milliliter (mL) of blood within the three months before screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Epithelial Lining Fluid (ELF) Concentration of Nacubactam to Plasma Concentration of Nacubactam Ratio | At 2, 3, 4, 6 and 8 hours after study drug administration | The ELF to plasma ratio will be calculated from the concentration of nacubactam in ELF and plasma as a measure of the intrapulmonary penetration of nacubactam in healthy participants. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clearance (CL) of Nacubactam | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Area Under the Plasma Concentration-Time Curve from Time 0 to 8 Hours (AUC0-8) of Nacubactam in Blood Plasma | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Maximum Concentration (Cmax) of Nacubactam in Blood Plasma | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Time to Reach the Maximum Plasma Concentration (Tmax) of Nacubactam | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Area Under the Plasma Concentration-Time Curve from time 0 to 8 hours (AUC0-8) of Nacubactam in ELF | At 2, 3, 4, 6 and 8 hours after study drug administration | — |
| ELF Concentration of Meropenem to Plasma Concentration of Meropenem Ratio | At 2, 3, 4, 6 and 8 hours after study drug administration | The ELF to plasma ratio will be calculated from the concentration of meropenem in ELF and plasma as a measure of the intrapulmonary penetration of meropenem in healthy participants.. |
| Volume of Distribution of the Central Compartment (Vc) of Nacubactam | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Volume of Distribution at Steady-State (Vss) of Nacubactam | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Maximum Concentration (Cmax) of Nacubactam in ELF | At 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Maximum Concentration (Cmax) of Meropenem in ELF | At 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Area Under the Plasma Concentration-Time Curve from Time 0 to 8 hours (AUC0-8) of Meropenem in Blood Plasma | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Maximum Concentration (Cmax) of Meropenem in Blood Plasma | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Time to Reach the Maximum Plasma Concentration (Tmax) of Meropenem | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Clearance (CL) of Meropenem | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Volume of Distribution of the Central Compartment (Vc) of Meropenem | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Volume of Distribution at Steady-State (Vss) of Meropenem | At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration | — |
| Number of Participants with Adverse Events | From baseline up to 14 days after study drug administration | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. |
| Area Under the Plasma Concentration-Time Curve from Time 0 to 8 Hours (AUC0-8) of Meropenem in ELF | At 2, 3, 4, 6 and 8 hours after study drug administration | — |
Countries
United States
Outcome results
None listed